Reuters exclusively reported that Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future. The hedge fund, which oversees some $60 billion in assets, has spent over $1 billion on the stake in BioMarin, which focuses on rare genetic disorders and is valued at about $16 billion.
Related stories
Exclusives | Americas
Read more
Peru plans bond sales to finance ballooning fiscal deficit, minister says
29 January 2025
News First | Americas
Read more
Boeing warns of bigger-than-expected $4 billion quarterly loss; shares drop
24 January 2025
Exclusives | Americas
Read more